Report Overview
Global Endobronchial Ultrasound Biopsy Device Market size is expected to be worth around US$ 2,097.6 Million by 2035 from US$ 927.8 Million in 2025, growing at a CAGR of 8.5% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 39.8% share with a revenue of US$ 369.6 Million.
The global Endobronchial Ultrasound (EBUS) Biopsy Device Market is experiencing steady growth as healthcare systems increasingly adopt minimally invasive technologies for the diagnosis and staging of lung diseases. Endobronchial ultrasound biopsy devices enable physicians to obtain tissue samples from lymph nodes and lung lesions with high precision, reducing the need for more invasive surgical procedures. The rising incidence of lung cancer, tuberculosis, and other respiratory disorders is a major factor driving market demand. Growing awareness of the importance of early and accurate diagnosis, along with expanding lung cancer screening programs, is further supporting market growth. Technological advancements in ultrasound imaging, bronchoscopy systems, and biopsy needle design are improving diagnostic accuracy, patient safety, and procedural efficiency. Hospitals, specialty pulmonary centers, and academic medical institutions are increasingly investing in advanced bronchoscopy equipment to enhance clinical outcomes. In addition, favorable clinical guidelines, increased healthcare expenditure, and ongoing research into innovative diagnostic technologies are creating new opportunities for market expansion. North America continues to lead the market due to its well-established healthcare infrastructure and high adoption of advanced diagnostic procedures, while Asia-Pacific is expected to witness strong growth driven by improving healthcare access, rising respiratory disease burden, and expanding investments in medical technology.
Click here for more information: https://market.us/report/endobronchial-ultrasound-biopsy-device-market/
Key Takeaways
- Market Value: The global Leadless Pacemakers Market is forecast to grow from US$ 807.8 million in 2025 to US$ 1,665.9 million by 2035.
- Growth Rate: The market is expected to register a CAGR of 7.5% throughout the 2026–2035 forecast period.
- By Product Type: Single-Chamber Leadless Pacemakers are projected to lead the market, accounting for 68.2% of the total market share in 2025.
- By Application: Bradycardia Treatment is anticipated to remain the dominant application segment, capturing 52.3% of the market in 2025.
- By Patient Type: The Pediatric segment is expected to hold the largest market share, contributing 49.5% in 2025.
- By End User: Hospitals are projected to dominate the market with a 55.9% revenue share in 2025, supported by the growing adoption of advanced cardiac rhythm management procedures.
- By Region: North America is expected to maintain its leading position in 2025, accounting for more than 43.3% of the global market and generating US$ 178.3 million in revenue.
Key Market Segments
- By Product Type
- EBUS Bronchoscopes
- EBUS Needles
- Aspiration Needles
- Biopsy Forceps
- Cytology Brushes
- EBUS Workstations and Processors
- Others
- By Usability
- Reusable
- Single-use
- By Application
- Lung Cancer Diagnosis and Staging
- Infectious Disease Diagnosis
- Mediastinal Lesion Biops
- Others
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
Market Key Players
- Olympus Corporation
- Boston Scientific Corporation
- Medtronic plc
- FUJIFILM Holdings Corporation
- Cook Medical, Inc.
- Pentax Medical (HOYA Group)
- CONMED Corporation
- Teleflex Incorporated
- Ambu A/S
- KARL STORZ SE & Co. KG
- Richard Wolf GmbH
- Medi-Globe GmbH
- Taewoong Medical Co., Ltd.
- Hobbs Medical, Inc.
- Micro-Tech Endoscopy USA, Inc.
- Others
Market Dynamics
Driver
The primary driver of the Endobronchial Ultrasound (EBUS) Biopsy Device Market is the increasing global burden of lung cancer and the growing emphasis on early, minimally invasive diagnosis. EBUS-guided transbronchial needle aspiration (EBUS-TBNA) enables physicians to obtain tissue samples from mediastinal lymph nodes and lung lesions with high diagnostic accuracy while avoiding more invasive surgical procedures. According to the World Health Organization (WHO), lung cancer remains one of the most commonly diagnosed cancers worldwide and is the leading cause of cancer-related deaths.
The International Agency for Research on Cancer (IARC) estimated approximately 2.5 million new lung cancer cases globally in 2022, representing around 12.4% of all new cancer diagnoses. The U.S. National Cancer Institute (NCI) estimates that more than 226,000 new lung and bronchus cancer cases are diagnosed annually in the United States. Clinical guidelines from organizations such as the American College of Chest Physicians (CHEST) recommend EBUS-TBNA as a first-line procedure for mediastinal staging in many patients with suspected lung cancer, driving increasing adoption of EBUS biopsy devices across hospitals and pulmonary centers.
Trend
A major trend shaping the Endobronchial Ultrasound (EBUS) Biopsy Device Market is the integration of advanced imaging technologies, navigation systems, and artificial intelligence (AI) into bronchoscopy procedures. Modern EBUS platforms increasingly combine real-time ultrasound imaging with electromagnetic navigation bronchoscopy (ENB), virtual bronchoscopy, and AI-assisted lesion detection to improve procedural accuracy. These technologies help physicians target smaller peripheral lung nodules while reducing unnecessary biopsies and procedure times.
According to the U.S. Food and Drug Administration (FDA), several advanced robotic and image-guided bronchoscopy systems have received regulatory clearance in recent years, reflecting ongoing technological progress. The National Lung Screening Trial (NLST) demonstrated that annual low-dose computed tomography (LDCT) screening reduced lung cancer mortality by approximately 20% among high-risk individuals, increasing the detection of small pulmonary nodules that often require tissue confirmation through EBUS-guided biopsy. As healthcare providers invest in digital operating rooms and precision diagnostics, demand for technologically advanced EBUS biopsy systems is expected to grow across academic hospitals and specialized respiratory care centers.
Restraint
Despite its clinical advantages, the Endobronchial Ultrasound (EBUS) Biopsy Device Market faces significant restraints due to the high cost of equipment, maintenance, and physician training. EBUS systems require specialized bronchoscopes, ultrasound processors, disposable biopsy needles, and highly trained pulmonologists, making adoption challenging for smaller hospitals and healthcare facilities with limited budgets. According to the World Health Organization (WHO), many low- and middle-income countries continue to experience shortages of advanced diagnostic technologies and specialized healthcare professionals.
The World Bank reports that healthcare expenditure varies widely across countries, limiting the availability of sophisticated diagnostic procedures in resource-constrained settings. In addition, establishing an EBUS program requires investment in staff training and procedural expertise to ensure accurate sampling and patient safety. Reimbursement differences across healthcare systems can also slow technology adoption. These financial and operational barriers restrict access to EBUS-guided procedures in underserved regions, leading many healthcare providers to rely on conventional bronchoscopy or surgical biopsy methods. Addressing affordability, workforce training, and infrastructure gaps remains essential for broader global adoption of EBUS biopsy devices.
Opportunity
The expansion of lung cancer screening initiatives and precision oncology presents a significant opportunity for the Endobronchial Ultrasound (EBUS) Biopsy Device Market. Governments and healthcare organizations are increasingly promoting low-dose CT (LDCT) screening for high-risk populations to improve early cancer detection. The U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for eligible adults aged 50 to 80 years with a significant smoking history, expanding the number of individuals undergoing evaluation for suspicious lung nodules. As more lesions are detected at earlier stages, the need for minimally invasive tissue sampling using EBUS-guided biopsy continues to rise. Furthermore, precision medicine requires adequate biopsy samples for molecular testing, including biomarkers such as EGFR, ALK, ROS1, and PD-L1, which guide targeted therapies and immunotherapy. According to the National Cancer Institute (NCI), biomarker testing has become a standard component of lung cancer management. Growing investments in cancer centers, increasing adoption of personalized treatment strategies, and expanding access to advanced diagnostic technologies in emerging economies are expected to create substantial long-term growth opportunities for EBUS biopsy device manufacturers.
Conclusion
The Endobronchial Ultrasound (EBUS) Biopsy Device Market is projected to experience robust growth as the demand for accurate, minimally invasive diagnostic procedures continues to increase. Rising incidence of lung cancer and respiratory diseases, combined with expanding lung cancer screening programs, is driving the adoption of EBUS-guided biopsy technologies. Advances in bronchoscopy systems, imaging capabilities, and precision diagnostics are further strengthening market development. As healthcare providers focus on early disease detection and personalized treatment strategies, the EBUS biopsy device market is expected to remain a key contributor to the future of respiratory diagnostics and oncology care.
Top comments (0)